ImmuCell Corporation ICCC
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +66.83%
- 1 year
- +68.47%
- Open
- 10.25
- Prev close
- 10.54
- Mkt cap
- 93.18M
- Vol
- 11.02K
- Avg vol
- 18.05K
- EPS
- 0.07
- P/E
- 146.57
- Div yield
- 0.00%
More statistics
- Low
- 9.98
- High
- 10.36
- Forward P/E
- -42.82
- Beta
- 0.57
- Short ratio
- 0.23
- Inst. own
- 14.51%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.93
- 200-d avg
- 4.28
- 1y target
- 0.00
News
1 week ago zacks.com
ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet?
Zoetis offers diversification and stability, while ImmuCell boasts stronger sales growth and expansion potential.
-
2 weeks ago benzinga.com
ImmuCell Reports Q3 Preliminary Sales Of $8M, Up 46% YoY
ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity,
2 weeks ago globenewswire.com
ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results
PORTLAND, Maine, Oct. 12, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets…
2 months ago zacks.com
ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2
ICCC's Q2 sales rise 11.5% y/y, but margins contract. A $2-million legal settlement boosts profit as the company plans a capacity expansion.
2 months ago defenseworld.net
ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell?
ImmuCell Corporation (NASDAQ: ICCC - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $8.64 and traded as…
2 months ago seekingalpha.com
ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript
ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript
2 months ago benzinga.com
ImmuCell Reports Q2 2026 Results: Full Earnings Call Transcript
ImmuCell (NASDAQ:ICCC) released second-quarter financial results and hosted an earnings call on Friday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive…
2 months ago marketbeat.com
ImmuCell Q2 Earnings Call Highlights
ImmuCell NASDAQ: ICCC reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while the company outlined plans to invest about $8…
-
2 months ago benzinga.com
ImmuCell Q2 EPS $0.20 Up From $0.06 YoY, Sales $7.186M Up From $6.445M YoY
ImmuCell (NASDAQ:ICCC) reported quarterly earnings of $0.20 per share. This is a 233.33 percent increase over earnings of $0.06 per share from the same period last year. The company reported $7.186…
2 months ago globenewswire.com
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
PORTLAND, Maine, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets…
2 months ago globenewswire.com
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026
PORTLAND, Maine, Aug. 06, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets…
3 months ago seekingalpha.com
ImmuCell: First Defense With Better Execution
ImmuCell's main value driver is First Defense. In my view, this is their core franchise and has real commercial momentum across year-round dairy customers. They've also shown improving manufacturing…
3 months ago zacks.com
ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand
ICCC reports an 11.5% rise in preliminary Q2 sales, driven by robust U.S. demand and improved product availability, extending the momentum from its strong Q1 performance.
-
3 months ago benzinga.com
ImmuCell Q2 Total Product Sales Rises 12%
ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity,
3 months ago globenewswire.com
ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results
PORTLAND, Maine, July 09, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets…
4 months ago zacks.com
ICCC's Valuation Remains Premium: Is it Worth Overpaying for?
ImmuCell's premium valuation is backed by rising output, First Defense share gains and a sizable untapped calf-health market opportunity.
5 months ago zacks.com
ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand
ICCC posts record Q1 sales and 34% earnings growth as demand for its First Defense calf-health products boosts margins and market share.
5 months ago marketbeat.com
ImmuCell Q1 Earnings Call Highlights
ImmuCell NASDAQ: ICCC reported a record first quarter of 2026, with management saying the company's narrowed focus on its First Defense calf scours prevention portfolio helped drive its first-ever…
5 months ago seekingalpha.com
ImmuCell Corporation (ICCC) Q1 2026 Earnings Call Transcript
ImmuCell Corporation (ICCC) Q1 2026 Earnings Call Transcript
-
5 months ago benzinga.com
ImmuCell Q1 EPS $0.21 Up From $0.16 YoY, Sales $10.357M Up From $8.067M YoY
ImmuCell (NASDAQ:ICCC) reported quarterly earnings of $0.21 per share. This is a 31.25 percent increase over earnings of $0.16 per share from the same period last year. The company reported $10.357…
5 months ago globenewswire.com
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
PORTLAND, Maine, May 14, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve…
-
5 months ago benzinga.com
ImmuCell And Norbrook Laboratories Reach Settlement Agreement, Norbrook To Pay $2M Following Expiration Of 2019 Supply Deal
On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims…
5 months ago globenewswire.com
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026
PORTLAND, Maine, May 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve…
6 months ago zacks.com
The Zacks Analyst Blog The Goldman Sachs, NextEra, Shopify, Landmark and ImmuCell
Goldman Sachs, NextEra Energy and Shopify lead top stock reports, highlighting strong gains, expanding operations and strategic shifts driving growth.
6 months ago globenewswire.com
ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors
PORTLAND, Maine, April 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve…
-
6 months ago benzinga.com
ImmuCell Reports Q1 Preliminary Sales $10.4M Up From 28.4% YoY
ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today…
6 months ago globenewswire.com
ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results
PORTLAND, Maine, April 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets…
-
8 months ago benzinga.com
ImmuCell Q4 EPS $(0.31) Down From $0.06 YoY, Sales $7.626M Down From $7.751M YoY
ImmuCell (NASDAQ:ICCC) reported quarterly losses of $(0.31) per share. This is a 616.67 percent decrease over earnings of $0.06 per share from the same period last year. The company reported $7.626…
-
-
9 months ago benzinga.com
ImmuCell Reports Q4 Preliminary Net Sales Of $7.6M; Domestic Sales Were $7.0M In 2025, An 8.7% Increase Compared To 2024
ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today…
-
10 months ago benzinga.com
ImmuCell Pauses Re-Tain Drug After FDA Setback, Shifts Focus to Expanding First Defense Business
ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it…
10 months ago benzinga.com
ImmuCell Puts Re-Tain On Pause After FDA Letter
Animal health company ImmuCell receives an Incomplete Letter from the FDA for its Re-Tain NADA. Company shifts focus to First Defense.
10 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
10 months ago benzinga.com
ImmuCell Has Decided To Pause Further Investment In Re-Tain
In seeking FDA approval to bring its innovative Re-Tain® product to market, ImmuCell received Complete Letters from the FDA for four of the five Technical Sections required for NADA approval. It…
-
10 months ago benzinga.com
ImmuCell Increasing First Defense Field Sales Force By 50%, Expanding First Defense Production Capabilities After Receiving FDA's Incomplete Letter For Its Re-Tain New Animal Drug Application
ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it received…
-
11 months ago benzinga.com
ImmuCell Q3 EPS $(0.02) Up From $(0.09) YoY, Sales $5.506M Down From $6.012M YoY
ImmuCell (NASDAQ:ICCC) reported quarterly losses of $(0.02) per share. This is a 77.78 percent increase over losses of $(0.09) per share from the same period last year. The company reported $5.506…
-
11 months ago benzinga.com
Earnings Scheduled For November 13, 2025
Earnings Scheduled For November 13, 2025
-
1 year ago benzinga.com
Earnings Scheduled For August 14, 2025
Earnings Scheduled For August 14, 2025
-
1 year ago benzinga.com
Earnings Scheduled For February 25, 2025
Earnings Scheduled For February 25, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
Earnings Scheduled For November 13, 2024
Earnings Scheduled For November 13, 2024
-
2 years ago benzinga.com
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
-
2 years ago benzinga.com
Earnings Scheduled For November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
-
3 years ago benzinga.com
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 199 companies reached new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
Thursday's session saw 337 companies set new 52-week lows.
-
3 years ago benzinga.com
Earnings Scheduled For February 21, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is likely to report earnings for its fourth quarter.